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ABSTRACT
The School of Graduate Studies
The University of Alabama in Huntsville

Degree: Doctor of Nursing Practice

College: Nursing

Name of Candidate: Minnetta Williams _______________________
Title:

Application of a Polycystic Ovarian Syndrome (PCOS) Diagnostic

Questionnaire in Clinical Practice
Introduction: Polycystic Ovarian Syndrome (PCOS) is the most common cause of
menstrual dysfunction and hyperandrogenism. PCOS is recognized as a
heterogeneous disorder that results in overproduction of androgens, primarily from
the ovaries and leads to anovulation, hirsutism, and insulin resistance. PCOS
diagnosis is challenging for providers because of the varying diagnostic criteria and
inconsistency of the patients’ complaints. A validated diagnostic screening
questionnaire would be very helpful in assisting providers in making a clinical
diagnosis of PCOS. The purpose is to have an effective diagnostic screening
questionnaire that can be used in any provider’s office to assist in diagnosing probable
PCOS. Objectives: The objectives were to determine how many Health Care
professionals (HCP’s) used the PCOS screening questionnaire to identify probable PCOS,
determine if questionnaire was helpful in diagnosing PCOS patients, identify feasibility of
the utilization of PCOS Screening questionnaire in clinical practice, and to identify barriers
in the use of the PCOS diagnostic screening questionnaire. Implementation Plan: Health
care professionals (Nurse Practitioners and Physicians) that worked in
Obstetrics/Gynecology and Family Practice/Adult Medicine participated in the study. A
pre-test was given to each provider before they started using the PCOS screening
questionnaire. The health care professional used the PCOS screening questionnaire in
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their office for 3 months with patients that had complaints of menstrual dysfunction,
hirsutism, obesity, or acne. At the conclusion of the 3 months, the health care provider
was given a post-test. All participation was voluntary. Results: Before participation in
the project, none of the providers had used a diagnostic PCOS screening
questionnaire. 62.5% of the health care providers diagnosed 1-5 patients with PCOS;
12.5% diagnosed 5-10 patients with PCOS; and 25% diagnosed >10 patients with
PCOS. Conclusion: All the health care providers found the PCOS screening
questionnaire to be helpful and effective in diagnosing PCOS patients and would
continue to use in their practice. In addition, the providers would recommend the
questionnaire to their colleagues.
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Application of a Polycystic Ovarian Syndrome (PCOS) Diagnostic Questionnaire
in Clinical Practice

Identification of the Problem
Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder
and cause of anovulatory infertility in childbearing age women (Tang et al., 2006).
This disease is complex and the exact physiology is unclear (Garad, Teede, & Moran,
2011). What is known about this condition is that hormone imbalance is the
underlying problem. Hyperandrogenism and insulin resistance contributes to the
etiology process of PCOS (Garad, Teede, & Moran, 2011). Women with PCOS can
present with polycystic ovaries, but it is not necessary for this diagnosis (Boyle &
Teede, 2012).
This population of women may have a plethora of symptoms and findings
related to their condition. According to Madnani, Khan, Chauhan, Parmar (2013), the
following signs and symptoms are common for women of reproductive age with
PCOS: metrorrhea or amenorrhea, acne, irregular menses, hirsutism, alopecia.
Additional symptoms included metabolic syndrome, obesity, insulin resistance,
acanthosis nigricans, Type 2 diabetes, dyslipidemias, hypertension, non-alcoholic
liver disease, and obstructive sleep apnea (Madnani et al., 2013).
Moran et al. (2009) reported PCOS affects 5-10% of women who are in the
reproductive age group. Occurring as young as 11, this condition has affected as many
as 5 million women of childbearing age in the US alone (Eisenburg, 2014).
According to Sirmans & Pate (2014) 30% of the PCOS population will experience
normal menses. Several studies have suggested that hypertension is more prevalent in
the PCOS population compared to the general population (Bentley-Lewis, Seely, &
Dunaif, 2011). According to Apridonidze, Essah, Iuorno, & Nestler (2005),
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hypertension represented 45% of the PCOS population. A common factor in PCOS is
obesity. Obesity seems to pose a higher risk for hypertension in the PCOS population.
Women with PCOS may lack a healthy vasculature secondary to a decrease in
nocturnal blood pressure (Bentley-Lewis, et al., 2011) and experience elevations in
their mean arterial and ambulatory systolic pressures (Carmina, 2009). Often times
PCOS is undiagnosed in women. This means that this population of women is
uneducated regarding their condition, possible co-morbidities, and treatment options.
It is imperative for health care providers to diagnose PCOS early to decrease risks for
comorbidities. Understanding some of the PCOS related comorbidities such as
obesity, hypertension, dyslipidemia, cancer, and Type 2 diabetes, will help this
population live a balanced and healthier life.
Apridonidze et al. (2005) reported obesity in 67% of women with PCOS. Obesity
seems to have increased over the years, which has had a big impact on the
development of chronic conditions such as metabolic syndrome, coronary heart
disease and type 2 diabetes (Apridonidze, et al., 2005). Reproductive health is
significantly impacted by obesity due to increased body weight that contributes to
ovulatory infertility. Overweight and obesity are commonly seen in PCOS women
(Apridonidze, et al., 2005). Having excess body weight can exacerbate symptoms of
PCOS such as hyperandrogenism, menstrual problems, infertility, insulin resistance,
dyslipidemia, increased risk of metabolic syndrome, impaired glucose tolerance, and
type 2 diabetes (Lim, Norman, Davies, & Moran, 2012).
Cardiovascular risk factors are significant among the PCOS population (Lim,
et al, 2012). The risk varies according to the levels of LDL, HDL, triglycerides, and
total cholesterol. Atherosclerosis has been reported to occur at higher rates in women
with PCOS (Lim, et al, 2012). It has been noted that early coronary and other vascular
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diseases has been documented in the PCOS population by different techniques (Lim,
et al, 2012). Some of the markers of vascular disease in the PCOS client are vessel
intima-media thickness, coronary artery calcification, echocardiography with
anatomic and functional differences, and impaired endothelial function (Apridonidze
et al., 2005).
Dyslipidemia is strongly associated with the PCOS population (Apridonidze et
al., 2005). According to data collected in a study by Apridonidze et al. (2005), 35% of
the PCOS population had elevated lipid levels. Triglycerides and the low-density
lipoproteins (LDL) were elevated above the normal limits and the high-density
lipoproteins (HDL) were decreased (Apridonidze et al., 2005). According to
Diamanti-Kandarakis, Papavassiliou, Kandarakis, and Chrousos, (2007), the National
Cholesterol Education Program (NCEP) guidelines stated that approximately 70% of
PCOS patients exhibit abnormal serum lipid levels. An unfavorable lipid profile that
consists of increased LDL, decreased HDL and increased total cholesterol and
triglyceride levels are associated with the elevated androgen and insulin levels found
in women with PCOS (Hart & Norman, 2006). Among the lifestyle and genetic
factors of PCOS, ethnicity has been shown to play a part in abnormal lipid profiles
(Diamanti-Kandarakis et al., 2007). A recent study showed that 36% of Mediterranean
patients with PCOS had abnormal lipid panels, which is significantly lower than US
PCOS patients (Diamanti-Kandarakis et al., 2007). Most PCOS patients have a family
history of PCOS. It is estimated that PCOS patients that have family members with a
metabolic disorder, have approximately a 2.7 higher chance of having dyslipidemia
than non PCOS patients. In this group, the development of dyslipidemia is
approximately 1.8 in family members with PCOS (Diamanti-Kandarakis, et al., 2007).
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Research has shown that the risk of endometrium, breast, and ovarian cancer is
associated with women with PCOS (Hoyt & Schmidt, 2004). Endometrial cancer
seems to be the greatest risk; it has been identified as being significant in PCOS
patients (Hoyt & Schmidt, 2004). Long periods of exposure to estrogen that is
unopposed could place someone to a risk of endometrial hyperplasia or cancer and
possibly breast cancer. Though the exact linkage of PCOS and breast cancer is still
unknown, some studies have suggested that chronic anovulation in the reproductive
years may increase the risk of breast cancer in the menopausal years (Hoyt &
Schmidt, 2004). The Cancer and Steroid Hormone study reported that patients with
ovarian cancer were likely to report a history of PCOS (Hoyt & Schmidt, 2004).
There is not enough research to support the theory and more studies are needed to
clarify the association.
Type 2 Diabetes and Impaired glucose tolerance is also prevalent in the PCOS
population. These patients have a 5 to 10-fold increased risk of developing Type 2
diabetes (Hoyt & Schmidt, 2004). It has been noted that there was a high prevalence
of first degree relatives with type 2 diabetes, which confirms family history as an
important risk factor (Hoyt & Schmidt, 2004). The overall presence of glucose
intolerance in the PCOS population is 30-35% and 3-10% with Type 2 diabetes (Hoyt
& Schmidt, 2004).
In order for this population to live a balanced life with PCOS, early detection
is necessary. This task is the responsibility of the health care provider. The PCOS
diagnosis can be challenging for health care providers because of the varying
diagnostic criteria and variance in patients’ complaints. Over the years, different
diagnostic criteria have been developed (Figure 1): a) National Institutes of Health
(NIH) 1990 which includes the following elements and both criteria needed for
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diagnosis: 1. chronic anovulation and 2. Clinical and/or biochemical signs of
hyperandrogenism (with exclusion of other etiologies) (National institutes of health,
2012); b) Rotterdam 2003 which includes the following criteria and two of three
criteria needed for diagnosis: 1. Oligo and/or anovulation 2. Clinical and/or
biochemical signs of hyperandrogenism 3. Polycystic ovaries (National institutes of
health, 2012); c) Androgen Excess & PCOS Society (AE-PCOS) 2006, which
includes the following criteria and (both criteria needed for diagnosis: 1. Clinical
and/or biochemical signs of hyperandrogensim 2. Ovarian dysfunction (oligoanovulation and/or polycystic ovarian amorphology) (National institutes of health,
2012). Rotterdam is used the most often and recommended by Legro et al. (2013) for
diagnosing PCOS. This criterion is most accepted because it is the most up-to-date
and it has a wider scope; this criterion includes both the NIH and AE-PCOS criteria
(National Institute of Health, 2012).
Figure 1. Diagnostic criteria for PCOS

According to Boyle and Teed (2012), individual components of the diagnostic
criteria for PCOS are difficult to measure. The Rotterdam criteria is used for PCOS
diagnosis include the following: androgen excess, ovulatory dysfunction, and
polycystic ovarian morphology (Boyle & Teede, 2012). Two of these are included as
a major component in all major classifications. Each one of the criteria has strengths
and limitations.
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There are strengths and limitations with using androgen excess as diagnostic
criteria (Figure 2). The strengths include the fact that androgen excess is a component
in all major classifications, it is a major concern for patients, and there are animal
models available for research (Boyle & Teede, 2012). The limitations include the fact
that androgen excess is only measurable through blood; concentrations of blood vary
from age to age and time to time; the assays are not standardized; and clinical
hyperandrogenism quantification is difficult and may vary dependent upon ethnicity
(Boyle & Teede, 2012). Ovulatory dysfunction also is a component in all
classifications (Boyle & Teede, 2012). Another strength of ovulatory dysfunction,
according to Boyle and Teede (2012), is that it is a common concern for patients and
infertility is common. Given ovulation is not totally understood, this is a limitation for
ovulatory dysfunction. Other limitations for ovulatory dysfunction is the fact that this
criterion is difficult to objectively measure and normal ovulation varies. Lastly, the
strength of polycystic ovarian morphology lie in the fact that this criterion,
historically, has been associated with PCOS and may be associated with
hypersensitivity to ovarian syndrome (Boyle & Teede, 2012). There are limitations
which can affect this criterion. The limitations include the lack of standardized and
normative measurements, imaging possibly inappropriate in certain circumstances,
and technology not universally available to accurately image (Boyle & Teede, 2012).
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Figure 2. Strengths and limitations of diagnostic criteria

The strengths and limitations of the PCOS diagnostic criteria can cause confusion
among health care professionals, which could delay the progress in understanding
PCOS and the ability to collaborate with women to address and manage their PCOS
health related issues. (National institutes of health, 2012). Once a patient has been
identified as someone with probable PCOS, the appropriate lab studies need to be
ordered and the diagnostic criteria (NIH 1990, Rotterdam 2003, or AE-PCOS Society
2006) can be applied to diagnose the patient. Also, the PCOS diagnostic screening
questionnaire would be very helpful to providers in making a clinical diagnosis of
probable PCOS and utilization of the PCOS evidence based PCOS guidelines could
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be used for information on how to treat the patient. Using the screening diagnostic
questionnaire for probable PCOS would help providers be more aware of patients that
have PCOS, possibly decrease the cost of ordering various lab studies that may not be
needed, and most of all, start early intervention to decrease PCOS related
comorbidities.

Purpose
The purpose of this project is to incorporate the PCOS diagnostic screening
questionnaire as a routine part of clinical care to diagnose probable PCOS patients.

Objectives
1- To assess the number of Health Care Professionals (HCP’S) that used the
PCOS screening questionnaire to identify probable PCOS patients.
2- To determine if the PCOS screening questionnaire was helpful in diagnosing
probable PCOS patients.
3- To identify the feasibility of utilization of PCOS Screening questionnaire
4- To identify barriers in the use of the PCOS diagnostic screening questionnaire.

PICOT question
Can the PCOS diagnostic screening questionnaire (Intervention) be effective in
assisting health care providers (population) to diagnose probable PCOS (outcome)?
Benefits: Ability to diagnose PCOS early and decrease comorbidities; ability to
educate patients early on preventive measures and lifestyle changes that will benefit
them.
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Review of Literature
The Methodology used was CINAHL, Ebsco, PubMed, and MEDLINE
databases were used. The key words were Polycystic Ovarian Syndrome, PCOS,
PCOS guidelines, PCOS diagnostic criteria, and PCOS diagnostic tools.
In 2007, Pederson, Brar, Faris, and Corenblum did a study in Calgary to
validate a simple questionnaire to use in screening women for the possible presence of
PCOS (2007). At that time there were not any validated tools available in the
literature to assist in making the clinical diagnosis of PCOS (Pederson, Brar, Faris,
and Corenblum, 2007). They constructed a 4-item questionnaire for the use of
diagnosing PCOS. The participants completed a questionnaire that asked questions
designed to assist in the diagnosis of PCOS before their appointment with an
endocrinologist. Participants were adult women, age 18 years old or older, who were
referred to a reproductive endocrinologist for menstrual irregularity, fertility concerns,
and hirsutism. The questionnaire was administered in 2 parts: The first part requested
demographic information and a medical history including specific questions regarding
known diagnoses of diabetes, hypertension, and dyslipidemia. The second part
requested menstrual and fertility history; questions were asked relating to frequency
of menses, history of failed attempts of pregnancy, history, sites, and treatment of
coarse midline hair growth and acne, history of breast discharge, obesity, and
variability of symptoms with weight change (Pederson, Brar, Faris & Corenblum,
2007). The endocrinologist completed their assessment with the standard diagnostic
criteria (NIH criteria) without knowing the answers to the 4-item questionnaire. The
endocrinologists made a diagnosis of PCOS using clinical criteria and biochemical
data. The history of infrequent menses, hirsutism, obesity, and acne were strong
predictors of a diagnosis of PCOS. The questionnaire yielded a sensitivity of 85% and
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a specificity of 85% on multivariate logistic regression and a sensitivity of 77% and a
specificity of 94% using the 4-item questionnaire (Pederson, Brar, Faris &
Corenblum, 2007). Findings from the study included a validated tool that providers
can use to help diagnose PCOS and can guide them in treating menstrual irregularity,
infertility, and cosmetic concerns (Pederson, Brar, Faris & Corenblum, 2007). The
tool can be used to alert providers to screen for associated and potentially devastating
comorbid conditions (Pederson, Brar, Faris & Corenblum, 2007). A positive result
from the questionnaire should prompt a careful clinical assessment for metabolic and
neoplastic complications of PCOS; a negative result does not rule out PCOS with
certainty and must be referred to the appropriate specialist (Pederson, Brar, Faris &
Corenblum, 2007). Another conclusion of the study was that the questionnaire could
be incorporated into family physician's busy practices (Pederson, Brar, Faris &
Corenblum, 2007). The researchers recommend further utilization and analysis of this
tool to further assess its validity.
In Australia, it was noted that there were limited clinical guidelines and no
evidence-based guidelines internationally for the assessment or management of
women with PCOS (Teede et al., 2011). The PCOS Australian Alliance in
conjunction with the Jean Hailes Foundation for Women’s Health developed an
Evidence-based guideline for the assessment and management of PCOS to help
providers make timely diagnosis, accurate assessments, and optimal management of
women with PCOS (“Evidence-based guideline,” 2011). This guideline was
developed by drawing from clinicians' judgement, patient preference and research
evidence, and was intended to aid in clinical judgement and patient preference, not to
replace it (Teede et al., 2011). Although there are many types of guidelines, this
evidence-based guideline followed a rigorous, systematic process of development and
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promoted consistency of care across all settings (Teede et al., 2011). The guideline is
meant to be relevant to the assessment and management of reproductive-age
adolescents and women with PCOS, including those experiencing infertility (Teede et
al., 2011). These guidelines are applicable to all health care settings and various
health care professionals. The Australian evidence-based PCOS guidelines provides
38 recommendations that address four key areas: Challenges of assessment and
diagnosis, assessment of emotional wellbeing, lifestyle management, and therapy for
infertility.
Tomlinson et al., 2017, performed a study on women with PCOS to identify
how they were diagnosed and how their experience was with living a life with PCOS.
It was thought that women with PCOS remain undiagnosed and are never referred for
further investigation and treatment (Tomlinson et al., 2017). Therefore, significant
health benefits could be achieved by improving recognition and detection of PCOS
(Tomlinson et al., 2017). The study was used to identify possible strategies to improve
PCOS detection and treatment. Women with PCOS were recruited from primary care,
gynecology, endocrinology, and weight management clinics. The PCOS diagnosis
was confirmed by using the Rotterdam criteria prior to the study. The study included
women with a wide range of body mass index (BMI), who were between 18-45 years
(Tomlinson et al., 2017). The results of the study revealed perceived delays and
barriers to PCOS diagnosis: most women felt that they were diagnosed in their midtwenties but had had signs and symptoms of PCOS for several years before; lack of
empathy from the doctors; and received limited information about PCOS from their
doctors (Tomlinson et al., 2017). The study also suggested significant concerns
surrounding diagnosis, treatment and relationships with healthcare professionals
(Tomlinson et al., 2017). According to Tomlinson et al., the concerns were associated
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with considerable uncertainty, perceived delays and barriers, inadequate advice and a
lack of accurate information (2017). Overall, the study suggested the need for
increased education for healthcare professionals both in relation to the physical and
emotional consequences of PCOS and in terms of patient/health professional
interaction (Tomlinson et al., 2017).
A study was performed to assess PCOS diagnostic criteria and antimullerian
hormone (AMH). The prevalence of PCOS can vary according to diagnostic
consensus used, with estimates ranging from 9% according to National Institutes of
Health consensus, up to 18% with the Rotterdam consensus (Mohammad &
Seghinsara, 2017). In another study, the utility of AMH in combination with PCOS
features for diagnosis of PCO was assessed (Sahmay et al., 2014). When the AMH
was evaluated among the patients diagnosed with PCOS according to all three
diagnostic criteria (the Rotterdam, Androgen Excess Society and National Institute of
Health) as a single screening tool, it had relatively low sensitivity and specificity for
diagnosis of PCOS (Mohammad & Seghinsara, 2017). It was suggested that
satisfactory diagnostic potential could be achieved by combining the AMH level with
other clinical symptoms (Mohammad & Seghinsara, 2017). The Rotterdam Criteria
considers the antral follicle count (AFC) on ultrasound as one of the diagnostic
criteria. Today’s technology of ultrasounds has improved and accuracy has increased,
but the number of follicles seen in ultrasound increase too, depending on the specific
equipment (Mohammad & Seghinsara, 2017). Serum AMH is synthesized by small
antral follicles, which are precisely seen in ultrasound. However, even with the most
advanced ultrasounds devices, the evaluation of polycystic ovarian morphology for
diagnosis of PCOS has high variability and can be difficult to count antral follicles
trans-abdominally in patients that have never been sexually active or patients that are
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obese (Mohammad & Seghinsara, 2017). There is an absence of a worldwide standard
for serum AMH assay, which makes the application of serum AMH level difficult
(Mohammad & Seghinsara, 2017). The study concluded although there is a lack of
well-defined population, stability and heterogeneity of circulating AMH, wide range
of values, inter-laboratory variability and different immunoassay used worldwide,
AMH could still be introduced as a criterion for PCOS diagnosis (Mohammad &
Seghinsara, 2017).

Theoretical Framework
Rosswurm and Larrabee proposed a model for guiding nurses and healthcare
professionals through a systematic process for the change to evidence-based practice
(1999). This model recognized that translation of research into practice requires a
solid grounding in change theory, principles of research utilization, and use of
standardized nomenclature (Rosswurm & Larrabee, 1999). This model is based on
theoretical and research literature related to evidence-based practice, research
utilization, standardized language, and change theory (Figure 3). With many changes
in the healthcare field, providers can no longer rely solely on clinical experience,
pathophysiologic rationale, and opinion based processes (Rosswurm & Larrabee,
1999). It is imperative that providers learn to search for literature, critically appraise
the findings, and synthesize the relevant evidence. The model has the following six
phases (Rosswurm & Larrabee, 1999):
Figure 3. Rosswurm & Larabee Model for change to Evidence-Based Practice
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1. Assess need for change in practice – Need to include stakeholders that may consist
of discipline-specific or multidisciplinary practitioners, administrators, and patients
who have a stake in the practice. Practitioners need to collect internal data and
compare it with external data to identify the problem within practice.
Figure 4. Conceptual Framework

2. Link problem with interventions and outcomes - Define the problem by using
language of standardized classifications and link the problem with classifications of
interventions and outcomes. This will facilitate communications among practitioners;
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provide standards for determining the effectiveness and cost of care, and identify the
needed resources. Potential interventions and activities can be identified and outcome
indicators can be selected.
3. Synthesize best evidence – The problem, potential interventions, and desired
outcomes are critical in reviewing research literature. Research synthesis helps to
determine the strength of the evidence to support the need for a change in practice.
4. Design a change in practice – A protocol, procedure, or standard is needed to help
facilitate a change in practice to describe the process variables or sequence of
activities in the change in practice. Relevant resources need to be identified and
outcomes defined.
5. Implementing and evaluating change in practice – Pilot trial should be initiated
with follow-up reinforcement of the practice change. Processes and outcomes need to
be evaluated. In this phase, a decision should be made to adapt, adopt, or reject the
practice change.
6. Integrate and maintain change in practice – Communicate recommended change to
all stakeholders. If pilot trial results are positive, change strategies need to be
identified. Monitor process and outcomes.
Many providers are treating symptoms of PCOS and not testing for or
diagnosing PCOS. This is the reason that many patients that have PCOS are
undiagnosed and are never educated on the comorbidities related to PCOS. It would
be very helpful and important utilize a screening diagnostic PCOS questionnaire into
practice. This would help with early PCOS diagnosis, and treatment and patient
education.
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SECTION II: SCHOLARY PROJECT PRODUCT
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JNP - The Journal for Nurse Practitioners
A.

Aims and Scope

JNP, the Journal for Nurse Practitioners, offers high-quality, peer-reviewed clinical
articles, original research, continuing education, and departments that help
practitioners excel as providers of primary and acute care across the lifespan. Each
issue meets their practice needs and encourages discussion and feedback with
thought-provoking articles on controversial issues and topics. JNP supports advocacy
by demonstrating the role that policy plays in shaping practice and delivering
outcomes.
The journal is published 10 times per year, distributed to approximately 100,000
readers in print form, and can be found online at www.npjournal.org. The journal is
included in Scopus, CINAHL, and the Journal Citation Report published by Thomson
Reuters.
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Application of a Polycystic Ovarian Syndrome (PCOS) Diagnostic Questionnaire
in Clinical Practice

Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder
and cause of anovulatory infertility in childbearing age women (Tang et al., 2006).
This disease is complex and the exact physiology is unclear (Garad, Teede, & Moran,
2011). What is known about this condition is that hormone imbalance is the
underlying problem. Hyperandrogenism and insulin resistance contributes to the
etiology process of PCOS (Garad, Teede, & Moran, 2011). Women with PCOS can
present with polycystic ovaries, but it is not necessary for this diagnosis (Boyle &
Teede, 2012).
This population of women may have a plethora of symptoms and findings
related to their condition. According to Madnani, Khan, Chauhan, Parmar (2013), the
following signs and symptoms are common for women of reproductive age with
PCOS: metrorrhea or amenorrhea, acne, irregular menses, hirsutism, alopecia.
Additional symptoms included metabolic syndrome, obesity, insulin resistance,
acanthosis nigricans, Type 2 diabetes, dyslipidemias, hypertension, non-alcoholic
liver disease, and obstructive sleep apnea (Madnani et al., 2013).
Apridonidze et al. (2005) reported obesity in 67% of women with PCOS.
Obesity seems to have increased over the years, which has had a big impact on the
development of chronic conditions such as metabolic syndrome, coronary heart
disease and type 2 diabetes (Apridonidze, et al., 2005). Reproductive health is
significantly impacted by obesity due to increased body weight that contributes to
ovulatory infertility. Overweight and obesity are commonly seen in PCOS women
(Apridonidze, et al., 2005). Having excess body weight can exacerbate symptoms of
PCOS such as hyperandrogenism, menstrual problems, infertility, insulin resistance,
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dyslipidemia, increased risk of metabolic syndrome, impaired glucose tolerance, and
type 2 diabetes (Lim, Norman, Davies, & Moran, 2012).
Cardiovascular risk factors are significant among the PCOS population (Lim,
et al, 2012). The risk varies according to the levels of LDL, HDL, triglycerides, and
total cholesterol. Atherosclerosis has been reported to occur at higher rates in women
with PCOS (Lim, et al, 2012). It has been noted that early coronary and other vascular
diseases has been documented in the PCOS population by different techniques (Lim,
et al, 2012).
Dyslipidemia is strongly associated with the PCOS population (Apridonidze et
al., 2005). According to data collected in a study by Apridonidze et al. (2005), 35% of
the PCOS population had elevated lipid levels. Triglycerides and the low-density
lipoproteins (LDL) were elevated above the normal limits and the high-density
lipoproteins (HDL) were decreased (Apridonidze et al., 2005). According to
Diamanti-Kandarakis, Papavassiliou, Kandarakis, and Chrousos, (2007), the National
Cholesterol Education Program (NCEP) guidelines stated that approximately 70% of
PCOS patients exhibit abnormal serum lipid levels. An unfavorable lipid profile that
consists of increased LDL, decreased HDL and increased total cholesterol and
triglyceride levels are associated with the elevated androgen and insulin levels found
in women with PCOS (Hart & Norman, 2006). Among the lifestyle and genetic
factors of PCOS, ethnicity has been shown to play a part in abnormal lipid profiles
(Diamanti-Kandarakis et al., 2007). A recent study showed that 36% of Mediterranean
PCOS patients had abnormal lipid panels; this is significantly lower than the abnormal
lipid panel of PCOS patients in the US (Diamanti-Kandarakis et al., 2007). Most
PCOS patients have a family history of PCOS. It is estimated that PCOS patients that
have family members with a metabolic disorder, have approximately a 2.7 higher
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chance of having dyslipidemia than non-PCOS patients. In this group, the
development of dyslipidemia is approximately 1.8 in family members with PCOS
(Diamanti-Kandarakis, et al., 2007).
Research has shown that the risk of endometrium, breast, and ovarian cancer is
associated with women with PCOS (Hoyt & Schmidt, 2004). Endometrial cancer
seems to be the greatest risk; it has been identified as being significant in PCOS
patients (Hoyt & Schmidt, 2004). It is thought that long periods of exposure to
estrogen that is unopposed could place someone to a risk of endometrial hyperplasia
or cancer and possibly breast cancer.
Type 2 Diabetes and Impaired glucose tolerance is also prevalent in the PCOS
population. These patients have a 5 to 10-fold increased risk of developing Type 2
diabetes (Hoyt & Schmidt, 2004). It has been noted that there was a high prevalence
of first-degree relatives with type 2 diabetes, which confirms family history as an
important risk factor (Hoyt & Schmidt, 2004). The overall presence of glucose
intolerance in the PCOS population is 30-35% and 3-10% with Type 2 diabetes (Hoyt
& Schmidt, 2004).
In order for this population to live a balanced life with PCOS, early detection
is necessary. This task is the responsibility of the health care provider. The PCOS
diagnosis can be challenging for health care providers because of the varying
diagnostic criteria and variance in patients’ complaints. Over the years, different
diagnostic criteria have been developed (Figure 1): a) National Institutes of Health
(NIH) 1990, which includes the following elements and both criteria needed for
diagnosis: 1. chronic anovulation and 2. Clinical and/or biochemical signs of
hyperandrogenism (with exclusion of other etiologies) (National institutes of health,
2012); b) Rotterdam 2003 which includes the following criteria and two of three
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criteria needed for diagnosis: 1. Oligo and/or anovulation 2. Clinical and/or
biochemical signs of hyperandrogenism 3. Polycystic ovaries (National institutes of
health, 2012); c) Androgen Excess & PCOS Society (AE-PCOS) 2006, which
includes the following criteria, and (both criteria needed for diagnosis: 1. Clinical
and/or biochemical signs of hyperandrogensim 2. Ovarian dysfunction (oligoanovulation and/or polycystic ovarian amorphology) (National institutes of health,
2012). Rotterdam is used more often and is recommended by Legro et al. (2013) for
PCOS diagnosis. This criterion is commonly used because it is the most up-to-date
and it has a wider scope; this criterion includes both the NIH and AE-PCOS criteria
(National Institute of Health, 2012).
According to Boyle and Teed (2012), individual components of the
diagnostic criteria for PCOS are difficult to measure. The Rotterdam criteria is used
for PCOS diagnosis include the following: androgen excess, ovulatory dysfunction,
and polycystic ovarian morphology (Boyle & Teede, 2012). Two of these are included
as a major component in all major classifications. Each one of the criteria has
strengths and limitations.
There are strengths and limitations with using androgen excess as diagnostic
criteria (Table 2). The strengths include the fact that androgen excess is a component
in all major classifications, it is a major concern for patients, and there are animal
models available for research (Boyle & Teede, 2012). The limitations include the fact
that androgen excess is only measurable through blood; concentrations of blood vary
from age to age and time to time; the assays are not standardized; and clinical
hyperandrogenism quantification is difficult and may vary dependent upon ethnicity
(Boyle & Teede, 2012). Ovulatory dysfunction also is a component in all
classifications (Boyle & Teede, 2012). Another strength of ovulatory dysfunction,
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according to Boyle and Teede (2012), is that it is a common concern for patients and
infertility is common. Given ovulation is not totally understood, this is a limitation for
ovulatory dysfunction. Other limitations for ovulatory dysfunction is the fact that this
criterion is difficult to objectively measure and normal ovulation varies. Lastly, the
strength of polycystic ovarian morphology lie in the fact that this criterion,
historically, has been associated with PCOS and may be associated with
hypersensitivity to ovarian syndrome (Boyle & Teede, 2012). There are limitations,
which can affect this criterion. The limitations include the lack of standardized and
normative measurements, imaging possibly inappropriate in certain circumstances,
and technology not universally available to accurately image (Boyle & Teede, 2012).
The strengths and limitations of the PCOS diagnostic criteria can cause
confusion among health care professionals, which could delay the progress in
understanding PCOS and the ability to collaborate with women to address and
manage their PCOS health related issues. (National institutes of health, 2012). Once a
patient has been identified as someone with probable PCOS, the appropriate lab
studies need to be ordered and the diagnostic criteria (NIH 1990, Rotterdam 2003, or
AE-PCOS Society 2006) can be applied to diagnose the patient. In addition, the
PCOS diagnostic screening questionnaire would be very helpful to providers in
making a clinical diagnosis of probable PCOS and utilization of the PCOS evidence
based PCOS guidelines could be used for information on how to treat the patient.
Using the screening diagnostic questionnaire for probable PCOS would help providers
be more aware of patients that have PCOS, possibly decrease the cost of ordering
various lab studies that may not be needed, and most of all, start early intervention to
decrease PCOS related comorbidities. Therefore, the purpose of this project is to
incorporate the PCOS diagnostic screening questionnaire as a routine part of clinical
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care to diagnose probable PCOS patients. This project was designed to answer the
following PICOT question: Can the PCOS diagnostic screening questionnaire be
effective in assisting providers to diagnose PCOS?

Review of Literature
The Methodology used was CINAHL, Ebsco, PubMed, and MEDLINE
databases were used. The key words were Polycystic Ovarian Syndrome, PCOS,
PCOS guidelines, PCOS diagnostic criteria, and PCOS diagnostic tools.
In 2007, Pederson, Brar, Faris, and Corenblum did a study in Calgary to
validate a simple questionnaire to use in screening women for the possible presence of
PCOS (2007). At that time, there were not any validated tools available in the
literature to assist in making the clinical diagnosis of PCOS (Pederson, Brar, Faris,
and Corenblum, 2007). They constructed a 4-item questionnaire for the use of
diagnosing PCOS. The participants completed a questionnaire that asked questions
designed to assist in the diagnosis of PCOS before their appointment with an
endocrinologist. Participants were adult women, age 18 years old or older, who were
referred to a reproductive endocrinologist for menstrual irregularity, fertility concerns,
and hirsutism. The questionnaire was administered in 2 parts: The first part requested
demographic information and a medical history including specific questions regarding
known diagnoses of diabetes, hypertension, and dyslipidemia. The second part
requested menstrual and fertility history; questions were asked relating to frequency
of menses, history of failed attempts of pregnancy, history, sites, and treatment of
coarse midline hair growth and acne, history of breast discharge, obesity, and
variability of symptoms with weight change (Pederson, Brar, Faris & Corenblum,
2007). The endocrinologist completed their assessment with the standard diagnostic
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criteria (NIH criteria) without knowing the answers to the 4-item questionnaire. The
endocrinologists made a diagnosis of PCOS using clinical criteria and biochemical
data. The history of infrequent menses, hirsutism, obesity, and acne were strong
predictors of a diagnosis of PCOS. The questionnaire yielded a sensitivity of 85% and
a specificity of 85% on multivariate logistic regression and a sensitivity of 77% and a
specificity of 94% using the 4-item questionnaire (Pederson, Brar, Faris &
Corenblum, 2007). Findings from the study included a validated tool that providers
can use to help diagnose PCOS and can guide them in treating menstrual irregularity,
infertility, and cosmetic concerns (Pederson, Brar, Faris & Corenblum, 2007). The
tool can be used to alert providers to screen for associated and potentially devastating
comorbid conditions (Pederson, Brar, Faris & Corenblum, 2007). A positive result
from the questionnaire should prompt a careful clinical assessment for metabolic and
neoplastic complications of PCOS; a negative result does not rule out PCOS with
certainty and should be referred to the appropriate specialist (Pederson, Brar, Faris &
Corenblum, 2007). Another conclusion of the study was that the questionnaire could
be incorporated into family physician's busy practices (Pederson, Brar, Faris &
Corenblum, 2007). The researchers recommend further utilization and analysis of this
tool to further assess its validity.
In Australia, it was noted that there were limited clinical guidelines and no
evidence-based guidelines internationally for the assessment or management of
women with PCOS (Teede et al., 2011). The PCOS Australian Alliance in
conjunction with the Jean Hailes Foundation for Women’s Health developed an
Evidence-based guideline for the assessment and management of PCOS to help
providers make timely diagnosis, accurate assessments, and optimal management of
women with PCOS (“Evidence-based guideline,” 2011). This guideline was
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developed by drawing from clinicians' judgement, patient preference and research
evidence, and was intended to aid in clinical judgement and patient preference, not to
replace it (Teede et al., 2011). Although there are many types of guidelines, this
evidence-based guideline followed a rigorous, systematic process of development and
promoted consistency of care across all settings (Teede et al., 2011). The guideline is
meant to be relevant to the assessment and management of reproductive-age
adolescents and women with PCOS, including those experiencing infertility (Teede et
al., 2011). These guidelines are applicable to all health care settings and various
health care professionals. The Australian evidence-based PCOS guidelines provides
38 recommendations that address four key areas: Challenges of assessment and
diagnosis, assessment of emotional wellbeing, lifestyle management, and therapy for
infertility.
Tomlinson et al., 2017, performed a study on women with PCOS to identify
how they were diagnosed and how their experience was with living a life with PCOS.
It was thought that women with PCOS remain undiagnosed and are never referred for
further investigation and treatment (Tomlinson et al., 2017). Therefore, significant
health benefits could be achieved by improving recognition and detection of PCOS
(Tomlinson et al., 2017). The study was used to identify possible strategies to improve
PCOS detection and treatment. Women with PCOS were recruited from primary care,
gynecology, endocrinology, and weight management clinics. The PCOS diagnosis
was confirmed by using the Rotterdam criteria prior to the study. The study included
women with a wide range of body mass index (BMI), who were between 18-45 years
(Tomlinson et al., 2017). The results of the study revealed perceived delays and
barriers to PCOS diagnosis: most women felt that they were diagnosed in their midtwenties but had had signs and symptoms of PCOS for several years before; lack of
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empathy from the doctors; and received limited information about PCOS from their
doctors (Tomlinson et al., 2017). The study also suggested significant concerns
surrounding diagnosis, treatment and relationships with healthcare professionals
(Tomlinson et al., 2017). According to Tomlinson et al., the concerns were associated
with considerable uncertainty, perceived delays and barriers, inadequate advice and a
lack of accurate information (2017). Overall, the study suggested the need for
increased education for healthcare professionals both in relation to the physical and
emotional consequences of PCOS and in terms of patient/health professional
interaction (Tomlinson et al., 2017).
A study was performed to assess PCOS diagnostic criteria and antimullerian
hormone (AMH). The prevalence of PCOS can vary according to diagnostic
consensus used, with estimates ranging from 9% according to National Institutes of
Health consensus, up to 18% with the Rotterdam consensus (Mohammad &
Seghinsara, 2017). In another study, the utility of AMH in combination with PCOS
features for diagnosis of PCO was assessed (Sahmay et al., 2014). When the AMH
was evaluated among the patients diagnosed with PCOS according to all three
diagnostic criteria (the Rotterdam, Androgen Excess Society and National Institute of
Health) as a single screening tool, it had relatively low sensitivity and specificity for
diagnosis of PCOS (Mohammad & Seghinsara, 2017). It was suggested that
satisfactory diagnostic potential could be achieved by combining the AMH level with
other clinical symptoms (Mohammad & Seghinsara, 2017). The Rotterdam Criteria
considers the antral follicle count (AFC) on ultrasound as one of the diagnostic
criteria. Today’s technology of ultrasounds has improved and accuracy has increased,
but the number of follicles seen in ultrasound increase too, depending on the specific
equipment (Mohammad & Seghinsara, 2017). Serum AMH is synthesized by small
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antral follicles, which are precisely seen in ultrasound. However, even with the most
advanced ultrasounds devices, the evaluation of polycystic ovarian morphology for
diagnosis of PCOS has high variability and can be difficult to count antral follicles
trans-abdominally in patients that have never been sexually active or patients that are
obese (Mohammad & Seghinsara, 2017). There is an absence of a worldwide standard
for serum AMH assay, which makes the application of serum AMH level difficult
(Mohammad & Seghinsara, 2017). The study concluded although there is a lack of
well-defined population, stability and heterogeneity of circulating AMH, wide range
of values, inter-laboratory variability and different immunoassay used worldwide,
AMH could still be introduced as criteria for PCOS diagnosis (Mohammad &
Seghinsara, 2017).

Theoretical Framework
Rosswurm and Larrabee proposed a model for guiding nurses and healthcare
professionals through a systematic process for the change to evidence-based practice
(1999). This model recognized that translation of research into practice requires a
solid grounding in change theory, principles of research utilization, and use of
standardized nomenclature (Rosswurm & Larrabee, 1999). This model is based on
theoretical and research literature related to evidence-based practice, research
utilization, standardized language, and change theory. With many changes in the
healthcare field, providers can no longer rely solely on clinical experience,
pathophysiologic rationale, and opinion based processes (Rosswurm & Larrabee,
1999). It is imperative that providers learn to search for literature, critically appraise
the findings, and synthesize the relevant evidence (Figure 3).
The model has the following six phases (Rosswurm & Larrabee, 1999):
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1. Assess need for change in practice – Need to include stakeholders that may consist
of discipline-specific or multidisciplinary practitioners, administrators, and patients
who have a stake in the practice. Practitioners need to collect internal data and
compare it with external data to identify the problem within practice.
2. Link problem with interventions and outcomes - Define the problem by using
language of standardized classifications and link the problem with classifications of
interventions and outcomes. This will facilitate communications among practitioners;
provide standards for determining the effectiveness and cost of care, and to identify
the needed resources. Potential interventions and activities can be identified and
outcome indicators can be selected.
3. Synthesize best evidence – The problem, potential interventions, and desired
outcomes are critical in reviewing research literature. Research synthesis helps to
determine the strength of the evidence to support the need for a change in practice.
4. Design a change in practice – A protocol, procedure, or standard is needed to help
facilitate a change in practice to describe the process variables or sequence of
activities in the change in practice. Relevant resources need to be identified and
outcomes defined.
5. Implementing and evaluating change in practice – Pilot trial should be initiated
with follow-up reinforcement of the practice change. Processes and outcomes need to
be evaluated. In this phase, a decision should be made to adapt, adopt, or reject the
practice change.
6. Integrate and maintain change in practice – Communicate recommended change to
all stakeholders. If pilot trial results are positive, change strategies need to be
identified. Monitor process and outcomes.
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Many providers are treating symptoms of PCOS and not testing for or
diagnosing PCOS. This is the reason that many patients that have PCOS are
undiagnosed and are never educated on the comorbidities related to PCOS. It would
be very helpful and important utilize a screening diagnostic PCOS questionnaire into
practice. This would help with early PCOS diagnosis, and treatment and patient
education.

Methodology
Study settings
In this scholarly project, a PCOS diagnostic screening questionnaire was
introduced in Ob/Gyn clinics to improve early PCOS diagnosis by incorporating the
questionnaire as a routine part of clinical screening. A convenience sampling method
was used to select 8 health care professionals (Doctors and Nurse Practitioners) from
selected clinics.
Study Instruments
The following instruments were used in the study:
1. A validated 4-item PCOS screening questionnaire (Pederson, Brar, Faris &
Corenblum, 2007) was used in the clinic to help screen women, age > 19, for possible
PCOS (Appendix A). The questionnaire was developed by Pederson, Brar, Faris, and
Corenblum in a research study titled “Polycystic ovary syndrome validated
questionnaire for use in diagnosis” that was published in Canadian Family Physician,
volume 53, June 2007 (Pederson et al, 2007). Permission to use the questionnaire was
obtained from Dr. Sue D. Pedersen via email. Each question was assigned a score
value 1, -1, or 0 and if the total score is > or equal to 2, the diagnosis is consistent
with PCOS and if the score is < 2, the diagnosis is not consistent with PCOS.
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2. A PCOS pre-test that consisted of 8 questions was administered to the health care
professional prior to the start of the study (Appendix B). The health care professionals
were asked to use the screening questionnaire in their practice for all female patients
and consider the helpfulness of the screening instrument in the diagnosis of PCOS.
3. A PCOS post-test that consisted of 8 questions was administered to the health care
professional at the conclusion of the study (Appendix C).
4. A Ferriman Gallwey Index chart tool was used to help assess for hirsutism.
Ferriman Gallwey Index is used for clinical assessment of hair growth in women and
to score the degree of excess male pattern body hair (Appendix D). The chart
represents hair growth in a male pattern on woman shown in four different degrees of
severity in 11 different body parts. Everybody part assessed is given a score that
ranges from 0 (no excessive terminal hair growth) to 4 (extensive terminal hair
growth). The numbers are added up to a maximum count of 36. A final score of 6 or
more is enough to indicate hirsutism.
5. A reference list of normal values was given for the laboratory investigation of
PCOS and information regarding how the ovaries should look in PCOS (Appendix E).
Procedure
The IRB granted approval for the proposal on September 26, 2016. After receiving
approval from the IRB to conduct the project, the PI started the study by recruiting health
care professionals that see the PCOS population. The PI obtained consent from the health
care professionals to participate in the study. Each health care professional was oriented
prior to the start of the study regarding the PCOS screening questionnaire process and
administration of the questionnaire. They were told that the questionnaire would only
take approximately 3-5 minutes to complete because it only consisted of only 4
questions and most health care professionals usually ask these questions when they
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see their patients. However, they usually do not score the findings. They were also
given educational materials that included the Ferriman Gallwey chart and PCOS
laboratory reference list. Before starting the project in their office, a pre-test was
given to the health care professional. The purpose for this pre-test was to identify
professional information and current PCOS diagnostic process. The health care
professionals were asked to utilize the diagnostic screening questionnaire in their
clinic for 3 months for patients that came to their clinic with complaints of menstrual
dysfunction, hirsutism, obesity, reproductive issues, acne, or any symptoms related to
PCOS for probable PCOS. Contact information for the PI was given to each health
care professional so that if any questions or problems arose, they would be able to
contact the PI. This study was considered a health care professional training activity,
where there was no patient interaction and no patient identification collected by the
PI. The questionnaire was a guide for the health care professionals and was not
collected by the PI. The health care professionals were educated on how to interpret
the results of the screening questionnaire. Educational materials were given that
included clinical assessment techniques and recommended lab tests to order after
identifying PCOS patients. Also, the health care professionals were given the
Ferriman Gallwey Index chart tool. The Ferriman Gallwey Index chart was used to
help assess for hirsutism. At the end of the 3-month period, the PI made contact with
the health care professionals to give them the posttest. The post-test was administered
to assess the feasibility of utilizing the questionnaire in practice, the number of
patients diagnosed with PCOS, and the continued use of the questionnaire in practice.
Evaluation
Each health care professional calculated the results of the PCOS screening
questionnaire upon completion of the 3-month study. If the response score was > or
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equal to 2, the diagnosis was consistent with PCOS, which meant the patient would
need further testing. If the questionnaire response was <2, the diagnosis was not
consistent with PCOS and other etiologies needed to be explored by the health care
professionals. Once all data had been collected, it was analyzed to determine the
efficacy of the screening questionnaire. The PI was able to determine if the PCOS
screening questionnaire was helpful in diagnosing probable PCOS patients.

Results
The PCOS scholarly project was conducted with eight health care
professionals that consisted of four medical doctors and four Nurse Practitioners. The
project took place in three family practice/adult medicine clinics and five
obstetrics/gynecology clinics. The PCOS screening questionnaire was utilized in their
clinics for three months and was used with patients that had symptoms related to
PCOS. Each health care professional that utilized the PCOS screening questionnaire
as a part of this scholarly project stated that it was helpful in identifying PCOS
patients. All eight health care professionals in their pre-test said that they had never
used a PCOS screening questionnaire prior to this study. They all said in their pre-test
that they used different methods to identify PCOS patients in their clinic such as
utilizing the Rotterdam criteria and clinical assessment. At the conclusion of this
study, each health care professional said in their post-test that they would continue to
utilize the PCOS screening questionnaire in their clinic. The PCOS screening
questionnaire helped the health care professionals to identify several PCOS patients
according to their post-test and it allowed them to devise a needed treatment plan for
their patients. The health care professionals in their post-test stated that they would
recommend the PCOS screening questionnaire to their colleagues.
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Discussion
The PCOS screening questionnaire was helpful to health care professionals in
identifying and diagnosing PCOS patients. The results indicated that 100% of the
health care professionals would continue to utilize the PCOS screening questionnaire
in their clinic. In addition, the results indicated that each provider would recommend
the questionnaire to their colleagues. In the original study by Pederson, Brar, Faris &
Corenblum, the 4-item questionnaire was validated as being useful in screening
women with menstrual irregularities, hirsutism, and other related findings for the
presence of PCOS (2007). Though, the questionnaire had not been validated in a
family practice setting, it was concluded that the questionnaire could be easily
incorporated into a busy family practice office (Pederson, Brar, Faris & Corenblum,
2007). In this scholarly project, 62.5% of the utilization of the screening tool took
place in an OBGYN clinic and 37.5% of the utilization occurred in Family
Practice/Adult primary care clinics. This tool was found to be effective in the
identification of women with PCOS.
Barriers
In order for the diagnostic screening tool to be used in a provider's office,
barriers need to be examined. A limitation of this scholarly project was participation
of health care professionals. Several forms of communication were used to recruit
health care professionals to participate in the project, which included electronic
means, face-to-face, other colleagues, and phone. Though approximately 20 health
care professionals were contacted, only 8 health care professionals were willing to
participate. Some of the health care professionals thought that utilizing the
questionnaire in their clinic for 3 months was too long and it would take too much
time away from their clinical practice time to administer the questionnaire.
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Sustainability Plan
In order to sustain this project in a clinical setting, the PCOS screening
questionnaire needs to be effective in diagnosing PCOS patients. Now that it has been
proven to be successful, it would be a great questionnaire to be used in assisting
providers to screen for PCOS and to diagnose it early in order to decrease the
comorbidities that accompany PCOS.
Benefits
This study was beneficial in providing a screening tool for HCPs to
utilize in the early diagnosis of clients with PCOS. By identifying these patients
early, health care professionals will be able to help decrease the comorbidities that
come with PCOS. An early and accurate diagnosis of PCOS would allow health care
professionals the ability to educate patients early on preventive measures and lifestyle
changes that would benefit them.
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Table 1.
Demographical and professional information
Variables

N

Health Profession:
Nurse Practitioner
Physician
Years of experience in health profession:

%

4
4

50
50

0-5 years
5-10 years
10-15 years
>15 years
Years of experience in current specialty:

2
1
1
4

25
12.5
12.5
50

0-5 years
5-10 years
10-15 years
>15 years
Specialty area:
OB/GYN
Family Practice
Adult primary care
Number of patients seen daily:
5-10
10-20
20-30
>30

2
2
1
3

25
25
12.5
37.5

5
2
1

62.5
25
12.5

1
4
3
0

12.5
50
37.5
0

3
2
1
2

37.5
25
12.5
25

Number of patients diagnosed with PCOS yearly:
0-10
10-20
20-30
>30

48

Table 2.
Diagnostic Criteria used to diagnose PCOS
Irregular periods or no periods; obesity, hirsutism, fasting insulin
Menstrual irregularity, hirsutism
History, exam, sonogram
Lab results, ultrasound, menstrual history, exam findings
Clinical findings, lab results
2/3 criteria: 1. Polycystic ovaries on ultrasound 2. Hirsutism 3. Irregular
menses
Menses, hair pattern, body shape, acne, fertility, facial features, transvaginal
or external ultrasound, labs
Ultrasound, patient symptoms
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Table 3.
Feasibility of utilization of PCOS Screening questionnaire
Variables
PCOS Screening questionnaire helpful in
identifying PCOS patients:
Yes
No
Number of probable PCOS patients identified:
0-5
5-10
>10
Number of patients diagnosed with PCOS:
0-5
5-10
>10
Utilization of the Ferriman-Gallwey Index chart
Yes
No
Have used previously
Utilization of the Laboratory Investigation of
PCOS reference list
No
Yes
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N

%

8
0

100
0

5
1
2

62.5
12.5
25

5
1
2

62.5
12.5
25

4
3
1

50
37.5
12.5

6
1

75
25

Table 4.
Health Care Professional’s recommendation of PCOS screening questionnaire
incorporation into clinical practice
Variables

N

PCOS screening questionnaire is an effective tool to
incorporate into clinic:
Yes
No
Recommendation of PCOS screening questionnaire to
colleagues:
Yes
No
Educational materials were helpful in diagnosing and treating
PCOS:
Yes
No
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%

8
0

100

8
0

100

8
0

100

Table 5.
Suggestions/Comments
The lab values and materials will be a quick access for screening and
diagnosis PCOS.
I do not recommend doing free testosterone. All the questions are
appropriate. When the diagnosis of PCOS is made on clinical basis, I do
several tests but not all tests (laboratory tests) on each patient.
Depending on whether they are on period or long-term amenorrhea,
order pregnancy test. I use my clinical judgment regarding pelvic
ultrasound and endometrial biopsy regarding their age, habitus, and
other symptoms.
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Figure 1.
Diagnostic Criteria for PCOS
NIH 1990
• Chronic
anovulation
• Clinical and/or
biochemical signs
of
hyperandrogenism
(with exclusion of
other etiologies,
e.g., congenital
adrenal
hyperplasia)
(Both criteria needed)

Rotterdam 2003
• Oligo- and/or
anovulation
• Clinical and/or
biochemical signs
of
hyperandrogenism
• Polycystic ovaries

(Two of three criteria
needed)
("National institutes of
health," 2012)

("National institutes of
health," 2012)
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AE-PCOS Society 2006
• Clinical and/or
biochemical signs
of
hyperandrogenism
• Ovarian
dysfunction (Oligoanovulation and/or
polycystic ovarian
morphology)
(Both criteria needed)
("National institutes of
health," 2012)

Figure 2.
Strengths and Limitations of diagnostic criteria
Diagnostic
Criteria
Androgen
Excess
("National
institutes of
health," 2012)

Ovulatory
Dysfunction
("National
institutes of
health," 2012)

Polycystic
Ovarian
Morphology
("National
institutes of
health," 2012)

Strengths
• Included as a
component in all
major
classifications
• A major clinical
concern for patients
• Animal models
employing
• androgen excess
resemble but do not
fully mimic human
disease
• Included as a
component in
all major
classifications
• A major clinical
concern for patients
• Infertility a
common clinical
complaint
• Historically
associated with
syndrome
• May be associated
with
hypersensitivity to
ovarian stimulation

Limitations
•
•
•
•
•

Measurement is performed only in blood.
Concentrations differ during time of day.
Concentrations differ with age.
Normative data are not clearly defined.
Assays are not standardized across
laboratories.
• Clinical hyperandrogenism is difficult to
quantify and may vary by ethnic group.
• Tissue sensitivity is not assessed.

• Normal ovulation is incompletely understood.
• Normal ovulation varies over a woman’s
lifetime.
• Ovulatory dysfunction is difficult to measure
objectively.

• Technique dependent
• Difficult to obtain standardized measurement
• Lack of normative standards across the
menstrual cycle and lifespan (notably in
adolescence) as ovarian morphology varies
with age
• Technology required to accurately image not
universally available Imaging possibly
inappropriate in certain circumstances (e.g.,
adolescence)
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Figure 3.
Rosswurm & Larabee Model for change to Evidence-Based Practice

55

Figure 4.
Conceptual Framework
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APPENDIX A
Screening Questionnaire for diagnosis of Polycystic Ovary Syndrome (PCOS)
CRITERIA TO
ATTAIN SCORE
VALUE

QUESTION

Please answer this question, NOT
INCLUDING any time spent pregnant,
receiving birth control pills or injections,
after menopause, or after having both
ovaries or the uterus surgically removed:
Between the ages of 16 and 40, about how
long was your average menstrual cycle
(time from first day of one period to the
first day of the next period)? (select ONE
only)
• <25 days
• 25-34 days
• 35-60 days
• More than 60 days
• Totally variable

Patient indicates any
one of

SCORE VALUE

1

• 35-60 d a ys
• More than 60
days
• Totally variable

During your menstruating years (not
including during pregnancy), did you
have a tendency to grow dark, coarse hair
on your (circle ALL that apply)
• Upper lip?
• Chin?
• Chest between the breasts?
• Back?
• Belly?
• Upper arms?
• Upper thighs?
Have you ever been obese or overweight
between the ages of 16 and 40? (circle
ONE)
• Yes
• No
Between the ages of 16 and 40, have
you ever noticed a milky discharge from
your nipples (not including during
pregnancy or recent childbirth)? (circle
ONE)
• Yes
• No

Patient
indicates 3 or
more sites

Patient indicates
Yes

Patient indicates Yes
Patient indicates No

TOTAL
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1

1

-1
0
If > 2, consistent with
diagnosis of PCOS
If < 2, not consistent
with diagnosis of
PCOS

Appendix B
PCOS Pre-test
Name:

Contact number:

1. What is your health profession?

a. Nurse Practitioner
b. Physician Assistant
c.

Nurse Midwife

d. Other
2. How many years of experience do you have in your health profession?

a. 0-5 years
b. 5-10 years
c.

10-15 years

d. > 15 years
3. How many years of experience in your current specialty area do you have?

a. 0-5 years
b. 5-10 years
c.

10-15 years

d. >15 years
4. Which specialty area is your clinic?

a. OB/GYN
b. Family Practice
c.

Other

5. How many patients do you currently see on a daily basis?

a.

5-10

b . 10-20
c . 20-30
d . > 30
6. How many patients do you diagnose with PCOS yearly in your clinic?

a 0-10
b 10-20
c 20-30
d >30
7. What diagnostic criteria do you use to diagnose PCOS?
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8. Do you use a PCOS diagnostic screening questionnaire to identify probable
PCOS patients based on symptoms?
Yes

No

If yes, what screening diagnostic questionnaire do you use?
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Appendix C
PCOS Post-test
Name:

Contact information:

1. Did you utilize the PCOS screening questionnaire with your patients to identify
PCOS patients?
Yes

No

I have used previously

If no, please explain
2. Was the screening questionnaire helpful in identifying PCOS patients?
Yes

No

I have used previously

If no, please explain
If yes, how many probable PCOS patients were identified?
a.

0-5

b . 5-10
c . >1 0
Of the above probable PCOS patients that were identified, how many of those
patients were diagnosed with PCOS?
a . 0 -5
b . 5-10
c . >10
3. Did you utilize the Ferriman-Gallwey Index chart to help diagnose hirsutism?
Yes

No

I have used previously

If no, please explain
4. Did you utilize the Laboratory Investigation of PCOS reference list?
Yes

No

I have used previously

If no, please explain
5. Do you think that the PCOS screening questionnaire would be an effective tool to
incorporate into your clinic?
Yes

No

6. Would you recommend the PCOS screening questionnaire to other colleagues?
Yes

No

7. Was the educational materials/information provided helpful in diagnosing and treating
PCOS?
Yes

No
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8. Any suggestions or comments?
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Appendix D
Ferriman Gallwey Index Chart
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Appendix E
Laboratory Investigation of PCOS Reference list

Test

Normal value

Purpose

β-hCG

< 5 mIU per mL (< 5
IU per L)

Exclude pregnancy

TSH

0.5 to 4.5 μU per mL
(0.5 to 4.5 mU per L)

Exclude thyroid
dysfunction

Prolactin

< 20 ng per mL (< 20 μ
g per L)

Exclude
hyperprolactinemia

Testosterone (total)

< 20 ng per dL (< 0.7
nmol per L)

Exclude androgensecreting neoplasm

Testosterone (free)

20 to 30 years—0.06 to
2.57 pg per mL (0.20 to
8.90 pmol per L)

Establish diagnosis
or monitor therapy

40 to 59 years—0.4 to
2.03 pg per mL (1.40 to
7.00 pmol per L)
DHEAS

600 to 3,400 ng per mL
(1.6 to 9.2 μmol per L)

Exclude androgensecreting neoplasm

Androstenedione

0.4 to 2.7 ng per mL
(1.4 to 9.4 nmol per L)

Establish diagnosis

17 αhydroxyprogesterone

Follicular phase < 2 μg
per L (6.1 nmol per L)

Exclude NCAH

Fasting insulin

< 20 μU per mL (< 144
pmol per L)

Exclude
hyperinsulinemia

Fasting glucose

65 to 119 mg per dL
(3.6 to 6.6 mmol per L)

Exclude type 2
diabetes or glucose
intolerance

Fasting glucose:
insulin ratio

@ 4.5

Exclude insulin
resistance
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Test

Normal value

Purpose

Cholesterol (total)

150 to 200 mg per dL
(1.5 to 2 g per L)

Monitor lifestyle
changes

HDL cholesterol

35 to 85 mg per dL (0.9
to 2.2 mmol per L)

Monitor lifestyle
changes

LDL cholesterol

80 to 130 mg per dL
(2.1 to 3.4 mmol per L)

Monitor lifestyle
changes

Pelvic
ultrasonography
Endometrial biopsy

Monitor lifestyle
changes
Negative for
hyperplasia/malignancy

Exclude
malignancy or
hyperplasia

note:Diagnosis of PCOS established by exclusion of other causes of oligomenorrhea
or hyperandrogenism. Other tests may be of benefit in monitoring therapy.
PCOS = polycystic ovary syndrome; β-hCG = beta subunit human chorionic
gonadotropin; TSH = thyroid-stimulating hormone; DHEAS =
dehydroepiandrosterone sulfate; NCAH = nonclassic adrenal hyperplasia; HDL =
high-density lipoprotein; LDL = low-density lipoprotein.

Pelvic ultrasound - ovarian volume greater than 10cm3 and/or 12 or more 2mm to 9
mm follicles.
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Appendix F
IRB Approval Letter

December 18th 2016
Minnetta Williams
College of Nursing
The University of Alabama in Huntsville
Dear Ms. Williams,
The UAH Institutional Review Board of Human Subjects Committee has
reviewed your proposal, Diagnostic Screening Questionnaire in Polycystic Ovarian
Syndrome (PCOS), and found it meets the necessary criteria for continued approval.
Your proposal seems to be in compliance with this institutions Federal Wide
Assurance (FWA) 00019998 and the DHHS Regulations for the Protection of Human
Subjects (45 CFR 46).
Please note that this approval is good for one year from the date on this letter.
If data collection continues past this period, you are responsible for processing a
renewal application a minimum of 60 days prior to the expiration date.
No changes are to be made to the approved protocol without prior review and
approval from the UAH IRB. All changes (e.g. a change in procedure, number of
subjects, personnel, study locations, new recruitment materials, study instruments,
etc) must be prospectively reviewed and approved by the IRB before they are
implemented. You should report any unanticipated problems involving risks to the
participants or others to the IRB Chair.
If you have any questions regarding the IRB’s decision, please contact me.

Sincerely,

William Wilkerson
IRB Chair
Dean, Honors College
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excerpts from other copyrighted works are included, the author(s) must
obtain written permission from the copyright owners and credit the
source(s) in the article. Elsevier has preprinted forms for use by authors in
these cases.

For open access articles: Upon acceptance of an article, authors will be
asked to complete an 'Exclusive License Agreement' (more information).
Permitted third party reuse of open access articles is determined by the
author's choice of user license.

Author rights
As an author you (or your employer or institution) have certain rights to
reuse your work. More information.
Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source

You are requested to identify who provided financial support for the conduct
of the research and/or preparation of the article and to briefly describe the
role of the sponsor(s), if any, in study design; in the collection, analysis and
interpretation of data; in the writing of the report; and in the decision to
submit the article for publication. If the funding source(s) had no such
involvement then this should be stated.
Please note that such information should appear on the Title Page. Generally,
articles that have been funded by business or industry or have received
professional editing support will be precluded from publication as features
but may be eligible for consideration as paid supplements.

Accountability

JNP requires all authors to acknowledge, on the Title Page of their
manuscript, all funding sources and/or granting agencies that supported
their work, as well as all institutional or corporate affiliations of all the
authors. Authors are also required to disclose to the Editor, in a covering letter
at the time of submission, any commercial associations that could pose a
conflict of interest or financial bias. These include consultation fees, patent
licensing arrangements, company stock, payments for conducting or
publicizing a study, travel, honoraria, gifts, or meals. If the article is
accepted for publication, the Editor will determine how any conflict of
interest should be disclosed. Authors are expected to fulfill the
requirements of their employer's publication policy before submitting their
manuscript. The Journal follows the ICMJE's Uniform Requirements for
Manuscripts Submitted to Biomedical Journals (http://www.icmje.org).
Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which
allow authors to comply with their funder's open access policies. Some
funding bodies will reimburse the author for the Open Access Publication Fee.
Details of existing agreements are available online.
After acceptance, open access papers will be published under a
noncommercial license. For authors requiring a commercial CC BY license,
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you can apply after your manuscript is accepted for publication.

Open access

This journal offers authors a choice in publishing their research:

Open access
• Articles are freely available to both subscribers and the wider public with
permitted reuse.
• An open access publication fee is payable by authors or on their behalf, e.g.
by their research funder or institution.
Subscription
• Articles are made available to subscribers as well as developing countries
and patient groups through our universal access programs.
• No open access publication fee payable by authors.

Regardless of how you choose to publish your article, the journal will apply
the same peer review criteria and acceptance standards.

For open access articles, permitted third party (re)use is defined by the
following Creative Commons user licenses:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and
to include in a collective work (such as an anthology), as long as they credit
the author(s) and provided they do not alter or modify the article.
The open access publication fee for this journal is USD 2500, excluding
Elsevier's
pricing
policy:
taxes.
Learn
more
about
http://www.elsevier.com/openaccesspricing.
Green open access
Authors can share their research in a variety of different ways and
Elsevier has a number of green open access options available. We
recommend authors see our green open access page for further
information. Authors can also self-archive their manuscripts immediately
and enable public access from their institution's repository after an embargo
period. This is the version that has been accepted for publication and which
typically includes author-incorporated changes suggested during submission,
peer review and in editor-author communications. Embargo period: For
subscription articles, an appropriate amount of time is needed for journals to
deliver value to subscribing customers before an article becomes freely
available to the public. This is the embargo period and it begins from the date
the article is formally published online in its final and fully citable form. Find
out more.
This journal has an embargo period of 12 months.
Language (usage and editing services)
Please write your text in good English (American or British usage is
accepted, but not a mixture of these). Authors who feel their English
language manuscript may require editing to eliminate possible grammatical
or spelling errors and to conform to correct scientific English may wish to use
the English Language Editing service available from Elsevier's WebShop.
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Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and
informed consent, which should be documented in the paper. Appropriate
consents, permissions and releases must be obtained where an author wishes
to include case details or other personal information or images of patients
and any other individuals in an Elsevier publication. Written consents must be
retained by the author and copies of the consents or evidence that such
consents have been obtained must be provided to Elsevier on request. For
more information, please review the Elsevier Policy on the Use of Images or
Personal Information of Patients or other Individuals. Unless you have
written permission from the patient (or, where applicable, the next of kin),
the personal details of any patient included in any part of the article and in
any supplementary materials (including all illustrations and videos) must be
removed before submission.
Also, please note that if an accepted article identifies a particular facility,
patient/client, etc, the author is responsible for securing written authorization
to use that name.

Student papers

Students are held to the same standards as other authors, and their
papers must be written in a scholarly format at the level for physician or
experienced NP readers. Student papers must meet the requirements of the
journal and be co-authored by a university faculty member who has worked
with the student to ensure the paper is in publishable form and that it
represents the best paper from their institution. Studies must have a
sufficiently developed methodology with large enough sample size to result in
valid conclusions that can be generalized beyond the sample itself. Pilot
studies are generally not acceptable, and authors with strong methodologies
are encouraged to continuing collecting data until they have enough data to
draw conclusions that warrant publication. If accepted, student papers will be
held for publication until the students have graduated.

JNP welcomes the submission of capstone projects that follow the guidelines
above. Authors of these projects should review Publishing a DNP capstone:
The where, what, and how before submission.

Submission

Our online submission system guides you stepwise through the process
of entering your article details and uploading your files. The system
converts your article files to a single PDF file used in the peer-review
process. Editable files (e.g., Word, LaTeX) are required to typeset your
article for final publication. All correspondence, including notification of the
Editor's decision and requests for revision, is sent by e-mail.
Submit your article
Please submit your article via http://ees.elsevier.com/jnp.

PREPARATION
Review process

Articles deemed potentially publishable will undergo double-blind peer review,
which means that both the reviewer and author name(s) are not allowed to
be revealed to one another for a manuscript under review. The identities of
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the authors are concealed from the reviewers, and vice versa. For more
information please refer to http://www.elsevier.com/reviewers/peer-review.
To facilitate this, please include the following separately:Title page (with
author details): This should include the title, authors' names and affiliations,
and a complete address for the corresponding author including telephone and
e-mail address.Blinded manuscript (no author details): The main body of
the
paper
(including
the references, figures, tables and any
acknowledgments) should not include any identifying information, such as the
authors' names or affiliations. Reviewers are asked to return their response
within 2 weeks but often require longer. Almost all submissions require
revision, which is to be completed within 30 days. Because of the intense
competition among articles, JNP has a commitment to make publication
decisions quickly; unrevised articles will not be allowed to remain indefinitely
in the system.

Essential Title Page information

Title - Be concise and informative. Titles are often used in informationretrieval systems. Avoid abbreviations and formulae where possible. Author
names, full credentials, and affiliations - Where the family name may be
ambiguous (eg, a double name), please clearly indicate given names and
surnames. Present the authors' affiliation addresses (where the actual work
was done) below the names. Indicate all affiliations, institutional and
corporate, with a lower-case superscript letter immediately after the
author's name and in front of the appropriate address. Provide the full postal
address of each affiliation, including the country name and, if available, the
e-mail address of each author. Author byline - Indicate which 2 credentials
each author would like after their name in the byline and table of contents
(eg, Joan Smith, MSN, PNP). Corresponding author - Clearly indicate who
will handle correspondence at all stages of refereeing and publication, also
post-publication. Ensure that phone numbers (with country and area
code) are provided in addition to the e- mail address and the
complete postal address. Contact details must be kept up to date by
the corresponding author. Present/permanent address. - If an author has
moved since the work described in the article was done, or was visiting at
the time, a 'Present address' (or 'Permanent address') may be indicated as
a footnote to that author's name. The address at which the author actually
did the work must be retained as the main, affiliation address. Superscript
Arabic numerals are used for such footnotes. Funding - Report all funding
sources and/or granting agencies that supported your work, as well as all
institutional or corporate affiliations of all the authors. Authors' full
credentials; authors' current job titles, employers, and the cities in which
they work; and the email address for the corresponding author will be listed
in the biography at the end of the article, so please be sure to include all
necessary information.
Highlights
Highlights are mandatory for this journal. They consist of a short
collection of bullet points that convey the core findings of the article and
should be submitted in a separate editable file in the online submission
system. Please use 'Highlights' in the file name and include 3 to 5 bullet
points (maximum 85 characters, including spaces, per bullet point). You
can view example Highlights on our information site.

Permissions

The author is responsible for obtaining written permission to use any
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copyrighted materials, including illustrations, photographs, tables, and any
content taken from websites. Documentation of permission to reprint
copyrighted materials should be submitted electronically when the article is
submitted. Additional information on securing permissions can be found at
http://www.elsevier.com/journal- authors/author-rights-and-responsibilities.
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's
requirements:
Funding: This work was supported by the National Institutes of Health [grant
numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant
number zzzz]; and the United States Institutes of Peace [grant number aaaa].
It is not necessary to include detailed descriptions on the program or type of
grants and awards. When funding is from a block grant or other resources
available to a university, college, or other research institution, submit the
name of the institute or organization that provided the funding.
If no funding has been provided for the research, please include the following
sentence:
This research did not receive any specific grant from funding agencies in the
public, commercial, or not-for-profit sectors.

Artwork Electronic artwork General points

• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times
New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published
version.
• Submit each illustration as a separate file.
A detailed guide on electronic artwork is available.
You are urged to visit this site; some excerpts from the detailed
information are given here.
Formats
If your electronic artwork is created in a Microsoft Office application (Word,
PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when
your electronic artwork is finalized, please 'Save as' or convert the images
to one of the following formats (note the resolution requirements for line
drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a
minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a
minimum of 1000 dpi. TIFF (or JPEG): Combinations bitmapped line/halftone (color or grayscale), keep to a minimum of 500 dpi.
Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT,
WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
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Please make sure that artwork files are in an acceptable format (TIFF (or
JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If,
together with your accepted article, you submit usable color figures then
Elsevier will ensure, at no additional charge, that these figures will appear in
color online (e.g., ScienceDirect and other sites) in addition to color
reproduction in print. Further information on the preparation of electronic
artwork.
Illustration services
Elsevier's WebShop offers Illustration Services to authors preparing to
submit a manuscript but concerned about the quality of the images
accompanying their article. Elsevier's expert illustrators can produce
scientific, technical and medical-style images, as well as a full range of
charts, tables and graphs. Image 'polishing' is also available, where our
illustrators take your image(s) and improve them to a professional standard.
Please visit the website to find out more.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not
attached to the figure. A caption should comprise a brief title (not on the
figure itself) and a description of the illustration. Keep text in the illustrations
themselves to a minimum but explain all symbols and abbreviations used.

Tables

Please submit tables as editable text and not as images. Tables can be
placed either next to the relevant text in the article, or on separate
page(s) at the end. Number tables consecutively in accordance with their
appearance in the text and place any table notes below the table body. Be
sparing in the use of tables and ensure that the data presented in them
do not duplicate results described elsewhere in the article. Please avoid
using vertical rules and shading in table cells.

References

Citation in text
Please ensure that every reference cited in the text is also present in the
reference list (and vice versa). Any references cited in the abstract must be
given in full. Unpublished results and personal communications are not
recommended in the reference list, but may be mentioned in the text. If these
references are included in the reference list they should follow the standard
reference style of the journal and should include a substitution of the
'Personal
publication
date
with
either
'Unpublished
results'
or
communication'. Citation of a reference as 'in press' implies that the item has
been accepted for publication.
Reference links
Increased discoverability of research and high quality peer review are
ensured by online links to the sources cited. In order to allow us to create
links to abstracting and indexing services, such as Scopus, CrossRef and
PubMed, please ensure that data provided in the references are correct.
Please
note that incorrect surnames, journal/book titles, publication year and
pagination may prevent link creation. When copying references, please be
careful as they may already contain errors. Use of the DOI is encouraged.
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A DOI can be used to cite and link to electronic articles where an article is
in-press and full citation details are not yet known, but the article is
available online. A DOI is guaranteed never to change, so you can use it as
a permanent link to any electronic article. An example of a citation using
DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James
D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser
Antilles slab beneath northeastern Venezuela. Journal of Geophysical
Research, https://doi.org/10.1029/2001JB000884. Please note the format
of such citations should be in the same style as all other references in the
paper.
Web references
At a minimum, the full URL should be given and the date when the
reference was last accessed. Any further information, if known (DOI, author
names, dates, reference to a source publication, etc), should also be given.
Web references should be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your
manuscript by citing them in your text and including a data reference in your
Reference List. Data references should include the following elements:
author name(s), dataset title, data repository, version (where available),
year, and global persistent identifier. Add [dataset] immediately before the
reference so we can properly identify it as a data reference. The [dataset]
identifier will not appear in your published article.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the
list (and any citations in the text) to other articles in the same Special Issue.
Reference management software
Most Elsevier journals have their reference template available in many of the
most popular reference management software products. These include all
products that support Citation Style Language styles, such as Mendeley
and Zotero, as well as EndNote. Using the word processor plug-ins from
these products, authors only need to select the appropriate journal
template when preparing their article, after which citations and
bibliographies will be automatically formatted in the journal's style. If no
template is yet available for this journal, please follow the format of the
sample references and citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal
by clicking the following link:
http://open.mendeley.com/use-citation-style/the-journal-for-nursepractitioners
When preparing your manuscript, you will then be able to select this style
using the Mendeley plug- ins for Microsoft Word or LibreOffice.
Reference formatting
There are no strict requirements on reference formatting at submission.
References can be in any style or format as long as the style is consistent.
Where applicable, author(s) name(s), journal title/book title, chapter
title/article title, year of publication, volume number/book chapter and the
pagination must be present. Use of DOI is highly encouraged. The
reference style used by the journal will be applied to the accepted article by
Elsevier at the proof stage. Note that missing data will be highlighted at proof
stage for the author to correct. If you do wish to format the references
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yourself they should be arranged according to the following examples:
Reference style
Text: Indicate references by (consecutive) superscript arabic numerals in
the order in which they appear in the text. The numerals are to be used
outside periods and commas, inside colons and semicolons. For further
detail and examples you are referred to the AMA Manual of Style, A Guide for
Authors and Editors, Tenth Edition, ISBN 0-978-0-19-517633-9.
List: Number the references in the list in the order in which they appear in
the text.
Examples:
Reference to a journal publication:
1. Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific
article. J Sci Commun.
2010;163:51–59.
Reference to a book:
2. Strunk W Jr, White EB. The Elements of Style. 4th ed. New York, NY:
Longman; 2000.
Reference to a chapter in an edited book:
3. Mettam GR, Adams LB. How to prepare an electronic version of your
article. In: Jones BS, Smith RZ, eds. Introduction to the Electronic Age. New
York, NY: E-Publishing Inc; 2009:281–304. Reference to a website:
4. Cancer Research UK. Cancer statistics reports for the UK.
http://www.cancerresearchuk.org/
aboutcancer/statistics/cancerstatsreport/; 2003 Accessed 13.03.03.
Reference to a dataset:
[dataset] 5. Oguro, M, Imahiro, S, Saito, S, Nakashizuka, T. Mortality data
for Japanese oak wilt disease and surrounding forest compositions,
Mendeley Data, v1; 2015. https://doi.org/10.17632/ xwj98nb39r.1.
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word
Abbreviations.

Video

Elsevier accepts video material and animation sequences to support and
enhance your scientific research. Authors who have video or animation files
that they wish to submit with their article are strongly encouraged to
include links to these within the body of the article. This can be done in the
same way as a figure or table by referring to the video or animation content
and noting in the body text where it should be placed. All submitted files
should be properly labeled so that they directly relate to the video file's
content. In order to ensure that your video or animation material is directly
usable, please provide the files in one of our recommended file formats with a
preferred maximum size of 150 MB. Video and animation files supplied will be
published online in the electronic version of your article in Elsevier Web
products, including ScienceDirect. Please supply 'stills' with your files: you can
choose any frame from the video or animation or make a separate image.
These will be used instead of standard icons and will personalize the link to
your video data. For more detailed instructions please visit our video
instruction pages. Note: since video and animation cannot be embedded in
the print version of the journal, please provide text for both the electronic and
the print version for the portions of the article that refer to this content.

Supplementary material

87

Supplementary material such as applications, images and sound clips, can
be published with your article to enhance it. Submitted supplementary items
are published exactly as they are received (Excel or PowerPoint files will
appear as such online). Please submit your material together with the article
and supply a concise, descriptive caption for each supplementary file. If you
wish to make changes to supplementary material during any stage of the
process, please make sure to provide an updated file. Do not annotate any
corrections on a previous version. Please switch off the 'Track Changes'
option in Microsoft Office files as these will appear in the published version.

AudioSlides

The journal encourages authors to create an AudioSlides presentation with
their published article. AudioSlides are brief, webinar-style presentations
that are shown next to the online article on ScienceDirect. This gives
authors the opportunity to summarize their research in their own words
and to help readers understand what the paper is about. More
information and examples are available. Authors of this journal will
automatically receive an invitation e-mail to create an AudioSlides
presentation after acceptance of their paper.

Submission requirements

Papers should be written in a scholarly format using references
generally no older than 5 years. Writing should be at the level for
physicians and experienced NPs.

Please prepare the following items for submission: Abstract - create a
concise and factual abstract that does not exceed 100 words and that
summarizes the article content. References should be avoided. Keywords List at least 5 words that best describe your article and would identify it
through a standard search engine. Cover letter - indicate who you are, a
very brief summary of your article, and why you believe it would fit with
JNP's mission; also state that the manuscript has not been and will not be
submitted elsewhere for publication. Conflict of interest statement - submit a
signed copy of the "Conflict of Interest" form that is found on the website as
you move through the submission process. Use a separate form for you and
each coauthor. Title page - include title of the manuscript; name of authors in
order in which they should appear; an affiliation, address, phone number,
and e- mail address for each author; author byline; and funding sources.
Please identify the corresponding author who will receive all correspondence.
Student authors should indicate their anticipated date of graduation. Word
count - create a page that lists only the total number of words in the
submission
—not just the main text. Blinded manuscript - make no reference to the
geographic location, the institution at which the work or study was conducted,
or any of the names or affiliations of the authors. Generic terms should be
used instead (region, university, medical center, etc). Tables and figures (if
appropriate) - separately label and save each table and hi-resolution figure
file. Figure legends (number and explanation) should be included at the end
of the blinded manuscript, not as part of the figure file. Identify sources for all
tables and submit written permission to publish copyrighted tables or images
that you wish to reprint or adapt.
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AFTER ACCEPTANCE
Proofs

One set of page proofs (as PDF files) will be sent by e-mail to the
corresponding author, or a link will be provided in the e-mail so that
authors can download the files themselves. Elsevier now provides authors
with PDF proofs which can be annotated; for this you will need to download
Reader
version
7
(or
higher)
available
free
from
Adobe
http://get.adobe.com/reader. Instructions on how to annotate PDF files will
accompany the proofs (also given online). The exact system requirements
are given at the Adobe site: http://www.adobe.com/products/reader/techspecs.html.
If you do not wish to use the PDF annotations function, you may list the
corrections (including replies to the Query Form) and return them to
Elsevier in an e-mail. Please list your corrections quoting line number. If,
for any reason, this is not possible, then mark the corrections and any other
comments (including replies to the Query Form) on a printout of your proof
and return by fax, or scan the pages and e-mail, or by post. Please use this
proof only for checking the typesetting, editing, completeness and
correctness of the text, tables and figures. Significant changes to the
article as accepted for publication will only be considered at this stage with
permission from the Editor. We will do everything possible to get your article
published quickly and accurately – please let us have all your corrections
within 48 hours. It is important to ensure that all corrections are sent back
to us in one communication: please check carefully before replying, as
inclusion of any subsequent corrections cannot be guaranteed. Proofreading
is solely your responsibility. Note that Elsevier may proceed with the
publication of your article if no response is received.

Offprints

The corresponding author will, at no cost, receive a customized Share Link
providing 50 days free access to the final published version of the article
on ScienceDirect. The Share Link can be used for sharing the article via
any communication channel, including email and social media. For an
extra charge, paper offprints can be ordered via the offprint order form
which is sent once the article is accepted for publication. Both
corresponding and co-authors may order offprints at any time via Elsevier's
Webshop. Corresponding authors who have published their article open
access do not receive a Share Link as their final published version of the
article is available open access on ScienceDirect and can be shared through
the article DOI link.

Disclaimers

All manuscripts are accepted for publication with the understanding that they
are contributed solely to JNP.
Statements and opinions expressed in the articles are those of the author(s)
and not necessarily those of the Editors, the American Association of Nurse
Practitioners (AANP), or Elsevier. The Editors, AANP, and Elsevier disclaim any
responsibility or liability for such material and do not guarantee, warrant, or
endorse any product or services advertised in this publication.
Manuscripts become the permanent property of JNP and may not be
published elsewhere without written permission from Elsevier. All accepted
manuscripts are subject to copyediting.
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AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you
will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when
your accepted article will be published.
© Copyright 2014 Elsevier | http://www.elsevier.com
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